Display options
Cite
Rivera JC, Strohbach CA, Wenke JC, et al. Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Front Pharmacol. 2013;4:125doi: 10.3389/fphar.2013.00125.
Rivera, J. C., Strohbach, C. A., Wenke, J. C., & Rathbone, C. R. (2013). Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Frontiers in pharmacology, 4125. https://doi.org/10.3389/fphar.2013.00125
Rivera, Jessica C, et al. "Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins." Frontiers in pharmacology vol. 4 (2013): 125. doi: https://doi.org/10.3389/fphar.2013.00125
Rivera JC, Strohbach CA, Wenke JC, Rathbone CR. Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Front Pharmacol. 2013 Oct 01;4:125. doi: 10.3389/fphar.2013.00125. eCollection 2013. PMID: 24101902; PMCID: PMC3787247.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2013 Oct 01;4:125. doi: 10.3389/fphar.2013.00125. eCollection 2013.

Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins.

Frontiers in pharmacology

Jessica C Rivera, Cassandra A Strohbach, Joseph C Wenke, Christopher R Rathbone

Affiliations

  1. Extremity Trauma and Regenerative Medicine, US Army Institute of Surgical Research, JBSA Fort Sam Houston, TX, USA.

PMID: 24101902 PMCID: PMC3787247 DOI: 10.3389/fphar.2013.00125

Abstract

Bone morphogenetic proteins (BMPs) other than the clinically available BMP-2 and BMP-7 may be useful for improving fracture healing through both increasing osteogenesis and creating a favorable healing environment by altering cytokine release by endogenous cells. Given the spectrum of potential applications for BMPs, the objective of this study was to evaluate various BMPs under a variety of conditions to provide further insight into their therapeutic capabilities. The alkaline phosphatase (ALP) activity of both C2C12 and human adipose-derived stem cells (hASCs) was measured after exposure of increasing doses of recombinant human BMP-2, -4, -5, -6, -7, or -9 for 3 and 7 days. BMPs-2, -4, -5, -6, -7, and -9 were compared in terms of their ability to affect the release of stromal derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (b-FGF) from human bone marrow stromal cells (hBMSCs). Gene expression of ALP, osteocalcin, SDF-1, VEGF, and b-FGF following shRNA-mediated knockdown of BMP-2 and BMP-6 in hBMSCs or human osteoblasts under osteogenic differentiation conditions was also evaluated. Collectively, BMPs-6 and -9 produced the greatest osteogenic differentiation of C2C12 and hASCs as determined by ALP. The hBMSC secretion of SDF-1 was most affected by BMP-5, VEGF by BMP-4, and b-FGF by BMP-2. The knockdown of BMP-2 in BMSCs had no effect on any of the genes measured whereas BMP-6 knockdown in hBMSCs caused a significant increase in VEGF gene expression. BMP-2 and BMP-6 knockdown in human osteoblasts caused significant increases in VEGF gene expression and trends toward decreases in osteocalcin expression. These findings support efforts to study other BMPs as potential bone graft supplements, and to consider combined BMP delivery for promotion of multiple aspects of fracture healing.

Keywords: angiogenesis; bone marrow stromal cell; bone morphogenetic protein; chemotaxis; osteoblast; osteogenesis

References

  1. Science. 1988 Dec 16;242(4885):1528-34 - PubMed
  2. J Bone Joint Surg Am. 2002 Dec;84(12):2123-34 - PubMed
  3. Blood. 2002 Oct 1;100(7):2597-606 - PubMed
  4. J Dent Res. 2008 Feb;87(2):107-18 - PubMed
  5. J Orthop Res. 2011 Jul;29(7):1064-9 - PubMed
  6. Biomed Mater. 2006 Sep;1(3):93-9 - PubMed
  7. Plast Reconstr Surg. 2002 Jun;109(7):2384-97 - PubMed
  8. Eur J Cell Biol. 2009 May;88(5):257-71 - PubMed
  9. Stem Cells Dev. 2009 May;18(4):545-59 - PubMed
  10. Science. 1965 Nov 12;150(3698):893-9 - PubMed
  11. Clin Orthop Relat Res. 1977 Jan-Feb;(122):307-14 - PubMed
  12. J Biomed Mater Res B Appl Biomater. 2006 Jan;76(1):230-9 - PubMed
  13. J Orthop Res. 2007 May;25(5):665-77 - PubMed
  14. J Bone Miner Res. 2002 Mar;17(3):513-20 - PubMed
  15. J Cell Biochem. 2006 Jun 1;98(3):538-54 - PubMed
  16. Gene Ther. 2004 Sep;11(17):1312-20 - PubMed
  17. Injury. 2011 Jun;42(6):551-5 - PubMed
  18. Tissue Eng. 2001 Apr;7(2):211-28 - PubMed
  19. J Dent Res. 1971 Nov-Dec;50(6):1392-406 - PubMed
  20. Cytokine Growth Factor Rev. 2009 Jun;20(3):203-12 - PubMed
  21. J Bone Joint Surg Am. 2003 Aug;85(8):1544-52 - PubMed
  22. Calcif Tissue Res. 1970;:Suppl:98-101 - PubMed
  23. J R Soc Interface. 2011 Feb 6;8(55):153-70 - PubMed
  24. Bone. 2007 Oct;41(4):516-22 - PubMed
  25. Curr Stem Cell Res Ther. 2012 May;7(3):165-72 - PubMed
  26. Gene Ther. 2003 Sep;10(20):1735-43 - PubMed
  27. Methods. 2001 Dec;25(4):402-8 - PubMed
  28. Calcif Tissue Int. 2008 Mar;82(3):238-47 - PubMed
  29. Biomaterials. 2009 Dec;30(35):6768-79 - PubMed

Publication Types